Results of Treatment of Venous Thromboembolic Complications in a Multidisciplinary Surgical Hospital of the Republic of Sakha (Yakutia)

Mikhail M. Vinokurov, Anton A. Yakovlev, Vasily P. Ignatiev, Natalia I. Douglas, Innokenty D. Ushnitsky, Gennady A. Palshin, Stepan S. Pavlov

International Journal of Biomedicine. 2019;9(3):260-262.   
DOI: 10.21103/Article9(3)_ShC2
Originally published September 15, 2019  


The article describes the main clinical risk factors for development of VTEC and the results of treatment in the Republic of Sakha (Yakutia) (RS(Y)).
The main risk factors for VTEC development were oncological diseases in 75/25.5% patients (15 of them with newly diagnosed cancer and 60 patients on the background of chemotherapy) and trauma of the musculoskeletal system in 55/18.7% patients. In the structure of DVT of the lower limbs, an occlusion was most often (112/38.2% patients) found in the ileal-femoral segments. PE was detected in 21 (7.1%) patients. Personalized anticoagulant therapy based on the results of pharmacogenetic testing for a specific patient increases the effectiveness and safety of treatment. Catheter-directed thrombolytic therapy for massive and submassive PE is the preferred method in the absence of contraindications for surgical hospitals. In patients with ascending varicotrombosis, phlebectomy combined with excision of thrombosed tributaries speeds up recovery and reduces the time until discharge from the hospital.

deep vein thrombosis • venous thromboembolic complications • pulmonary embolism • activated partial thromboplastin time
  1. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-74. doi: 10.1038/nrcardio.2015.83.
  2. Hansson PO, Welin L, Tibblin G, Eriksson H.Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med. 1997;157(15):1665-70.
  3. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25.
  4. Savelyev VS, Chazov EI, Gusev EI, Kirienko AI, Gelfand BR, Piradov MA, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2010;4(2):1-37.[Article in Russian].
  5. Russian clinical guidelines "Diagnosis, treatment and prevention of venous thromboembolic complications". Edited by A.I. Kirienko. Moscow; 2015. [In Russian].
  6. Kalinin RE, Suchkov IA, Pshennikov AS, Agapov AB. Quality of life of patients with venous thromboses at different variants of anticoagulant therapy. Angiology and Vascular Surgery. 2016;22(2):15-20. [Article in Russian].
  7. Cascorbi I. The promises of personalized medicine. Eur J Clin Pharmacol. 2010 Aug;66(8):749-54. doi: 10.1007/s00228-010-0858-6.
  8. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al.; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679.
  9. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445-53.

Download Article
Received July 16, 2019.
Accepted August 8, 2019.
©2019 International Medical Research and Development Corporation.